Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression

Journal of Medicinal Chemistry

Volumn 52, Issue 9, 2009, Pages 3112-3115

  Charrier, Cédric ^a   Clarhaut, Jonathan ^a   Gesson, Jean Pierre ^a   Estiu, Guillermina ^b   Wiest, Olaf ^b   Roche, Joëlle ^a   Bertrand, Philippe ^a  

^a UNIVERSITÉ DE POITIERS   (France)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (6 DIMETHYLAMINO 2 METHYL 3 OXO 2,3 DIHYDROBENZOFURAN 2 YL) 4 METHYLPENTA 2,4 DIENOIC ACID HYDROXAMIDE; BENZAMIDE DERIVATIVE; BENZOFURAN DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; HYDROXAMIC ACID DERIVATIVE; SEMAPHORIN 3F; UNCLASSIFIED DRUG; UVOMORULIN;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CULTURE MEDIUM; DRUG SYNTHESIS; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; REACTION ANALYSIS; TUMOR SUPPRESSOR GENE;

ACETYLATION; BENZOFURANS; CADHERINS; CATALYTIC DOMAIN; CELL LINE, TUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HUMANS; MEMBRANE PROTEINS; MODELS, MOLECULAR; NERVE TISSUE PROTEINS; TUBULIN; TUMOR SUPPRESSOR PROTEINS;

EID: 65649113311     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9002439     Document Type: Article

References (19)

1. (a) Baylin, S. B.; Ohm, J. E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction. Nat. Rev. Cancer 2006, 6, 107.
2. (b) Xu, W. S.; Parmigiani, R. B.; Marks, P. A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26, 5541.
3. Hodawadekar, S. C.; Marmorstein, R. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 2007, 26, 5528. (Pubitemid 47255933)
4. Dokmanovic, M.; Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 2007, 5, 981.
5. Duvic, M.; Talpur, R.; Ni, X.; Zhang, C.; Hazarika, P.; Kelly, C.; Chiao, J. H.; Reilly, J. F.; Ricker, J. L.; Richon, V. M.; Frankel, S. R. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109, 31.
6. (a) Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (London) 1999, 401, 188.
7. (b) Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B. C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004, 12, 1325.
8. Vannini, A.; Volpari, C.; Gallinari, P.; Jones, P.; Mattu, M.; Carf́, A.; De Francesco, R.; Steinkühler, C.; Di Marco, S. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep. 2007, 8, 879.
9. Nielsen, T. K.; Hildmann, C.; Dickmanns, A.; Schwienhorst, A.; Ficner, R. Crystal structure of a bacterial class 2 histone deacetylase homologue. J. Mol. Biol. 2005, 354, 107.
10. Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian, X.; Mills, E.; Berghs, S. C.; Carey, N.; Finn, P. W.; Collins, L. S.; Tumber, A.; Ritchie, J. W.; Jensen, P. B.; Lichenstein, H. S.; Sehested, M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409, 581.
11. KrennHrubec, K.; Marshall, B. L.; Hedglin, M.; Verdin, E.; Ulrich, S. M. Design and Evaluation of "Linkerness" Hydroxamic Acids as Selective HDAC8 Inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 2874.
12. (a) Kozikowski, A. P.; Tapadar, S.; Luchini, D. N.; Kim, K. H.; Billadeau, D. D. Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6. J. Med. Chem. 2008, 51, 4370-4373.
13. (b) Estiu, G.; Greenberg, E.; Harrison, C. B.; Kwiatkowski, N. P.; Mazitschek, R.; Bradner, J. E.; Wiest, O. Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors. J. Med. Chem. 2008, 51, 2898-2906.
14. (a) Weerasinghe, S. V. W.; Estiu, G.; Wiest, O.; Pflum, M. K. H. Residues in the 11 Å Channel of Histone Deacetylase 1 Promote Catalytic Activity: Implications for Designing Isoform-Selective Histone Deacetylase Inhibitors. J. Med. Chem. 2008, 51, 5542-5551.
15. (b) Witter, D.; Belvedere, S.; Chen, L.; Secrist, J.; Mosley, R.; Miller, T. A. Benzo[b]thiophene-based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 4562-4567.
16. (a) Charrier, C.; Bertrand, P.; Gesson, J.-P.; Roche, J. Synthesis of rigid trichostatin A analogs as HDAC inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 5339.
17. (b) Charrier, C.; Roche, J.; Gesson, J.-P.; Bertrand, P. Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. Bioorg. Med. Chem. Lett. 2007, 17, 6142. (Pubitemid 47552840)
18. Ohira, T.; Gemmill, R.; Ferguson, K.; Kusy, S.; Roche, J.; Brambilla, E.; Zeng, C.; Baron, A.; Bemis, L.; Erickson, P.; Wilder, E.; Rustgi, A.; Kitajewski, J.; Gabrielson, E.; Bremnes, R.; Franklin, W.; Drabkin, H. WNT7a induces E-Cadherin in lung cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10429.
19. Potiron, V.; Roche, J.; Drabkin, H. Semaphorins and their receptors in lung cancer. Cancer Lett. 2009, 273, 1.